[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 17, 1997

Bioequivalence of Levothyroxine Preparations: Issues of Science, Publication, and Advertising-Reply

Author Affiliations

Jones Medical Industries Inc St Louis, Mo

JAMA. 1997;278(11):899. doi:10.1001/jama.1997.03550110037028

In Reply.  —Dr Lankin seems to be under the impression that Levoxyl is a relatively unknown, underadvertised drug. To the contrary, of the top 200 prescribed drugs in the United States in 1996, Levoxyl was the 51st most often prescribed, up from 63rd in 1995.1 The same Levoxyl ad that appeared in the April 16, 1997, issue of JAMA comparing the price benefit between Levoxyl and Synthroid has appeared in Drug Topics, US Pharmacist, Journal of Clinical Endocrinology & Metabolism, Endocrine Practice, Thyroid, and PA Today for the past 2 years.Jones Medical Industries Inc is a public company that manufactures and markets pharmaceutical products. Yes, we do want to inform investors and prescribers about our company and the products we market. Consequently, our stock symbol appears on all public literature and advertisements.Obviously, Jones Medical Industries and Knoll Pharmaceutical were both notified of the publication date of the study conducted